Monthly Oncology Tumor Boards: Brain Metastases in Breast Cancer

December 9, 2021

Diagnosis of central nervous system involvement is increasing in patients with breast cancer as therapy for metastatic disease is improving. It is now reasonable to treat some patients with brain metastases (i.e., those with asymptomatic brain metastases) with systemic therapy upfront instead of upfront stereotactic radiosurgery or whole brain radiation therapy. Clinicians may be challenged when considering a trial of upfront systemic therapy alone for brain metastases, and a multidisciplinary discussion between medical and radiation oncology is recommended.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Recognize the presenting signs and symptoms of brain metastases in patients with breast cancer.
  • Describe the efficacy of stereotactic radiosurgery and whole brain radiation therapy for treatment of brain metastases, as well as potential effects on cognitive function and quality of life.
  • Identify systemic therapy options for patients with brain metastases from breast cancer.
Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Blueprint Medicines
  • Epizyme Inc.
  • GlaxoSmithKline
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Sanofi Genzyme

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Illumina, Inc
  • Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc. 

This activity is supported by an independent educational grant from Astellas.

This educational activity is supported by a medical education grant from Exelixis, Inc.
 

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
10/08/2021
Course expires: 
03/27/2022
Event starts: 
12/09/2021 - 1:00pm EST
Event ends: 
12/09/2021 - 2:00pm EST
Cost:
$0.00
Part of: 
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care (June 2021 - May 2022)
Add to calendar: 

Seema Nagpal, MD
Stanford Cancer Institute 

Erqi Pollom, MD, MS
Stanford Cancer Institute 

Melanie Hayden Gephart, MD, MAS
Stanford Cancer Institute

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Seema Nagpal, MD
Agios, Inc.: Grant/Research Support
Berg LLC: Grant/Research Support
Biocept, Inc.: Consulting Fee
Inovio Pharmaceuticals: Grant/Research Support
PharmAbcine Inc.: Grant/Research Support
Seattle Genetics, Inc.: Consulting Fee 

Erqi Liu Pollom, MD, MS
Genentech, Inc.: Grant/Research Support 

Melanie Hayden Gephart, MD, MAS
Quadriga BioSciences, Inc.: Grant/Research Support
SmarLens, Inc.: Royalty Income

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-21-042-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00048634; Approval #: 210004001

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Thursday, December 9, 2021, from 1:00 – 2:00 PM EST (UTC -5).
Click here to view the recorded activity.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing